AU1693783A

AU1693783A – Amides
– Google Patents

AU1693783A – Amides
– Google Patents
Amides

Info

Publication number
AU1693783A

AU1693783A
AU16937/83A
AU1693783A
AU1693783A
AU 1693783 A
AU1693783 A
AU 1693783A
AU 16937/83 A
AU16937/83 A
AU 16937/83A
AU 1693783 A
AU1693783 A
AU 1693783A
AU 1693783 A
AU1693783 A
AU 1693783A
Authority
AU
Australia
Prior art keywords
different
same
alkyl
hydrogen
acylanilides
Prior art date
1982-07-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Application number
AU16937/83A
Other versions

AU556328B2
(en

Inventor
Howard Tucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

AstraZeneca AB

Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1982-07-23
Filing date
1983-07-18
Publication date
1984-01-26
Family has litigation

First worldwide family litigation filed
litigation
Critical
https://patents.darts-ip.com/?family=10531878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU1693783(A)
“Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1983-07-18
Application filed by AstraZeneca AB
filed
Critical
AstraZeneca AB

1984-01-26
Publication of AU1693783A
publication
Critical
patent/AU1693783A/en

1986-10-30
Application granted
granted
Critical

1986-10-30
Publication of AU556328B2
publication
Critical
patent/AU556328B2/en

1994-06-23
Assigned to ZENECA LIMITED
reassignment
ZENECA LIMITED
Alteration of Name(s) in Register under S187
Assignors: IMPERIAL CHEMICAL INDUSTRIES PLC

2001-02-01
Assigned to ASTRAZENECA AB
reassignment
ASTRAZENECA AB
Alteration of Name(s) in Register under S187
Assignors: ZENECA LIMITED

2008-07-18
Adjusted expiration
legal-status
Critical

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 – C07D283/00

C07D285/01—Five-membered rings

C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles

C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings

C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles

C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P15/00—Drugs for genital or sexual disorders; Contraceptives

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P17/00—Drugs for dermatological disorders

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P5/00—Drugs for disorders of the endocrine system

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS

C07C255/00—Carboxylic acid nitriles

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS

C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS

C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS

C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups

C07C59/40—Unsaturated compounds

C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups

C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings

C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings

C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members

C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom

C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

C07D213/62—Oxygen or sulfur atoms

C07D213/70—Sulfur atoms

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings

C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members

C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

C07D233/84—Sulfur atoms

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings

C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members

C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

C07D239/32—One oxygen, sulfur or nitrogen atom

C07D239/38—One sulfur atom

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings

C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings

C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members

C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

C07D277/36—Sulfur atoms

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom

C07D303/02—Compounds containing oxirane rings

C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom

C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes

C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Abstract

Acylanilides of the formula wherein R1 and R2, the same or different, each is cyano, carbamoyl, nitro, halogeno, perfluoroalkyl or other defined substituents; R3 is hydrogen or halogen; R4 is hydrogen or alkyl, or is joined to R5; R5 is hydrogen, hydroxy, alkoxy or acyloxy or is joined to R4; R6 is alkyl or halogenoalkyl, or has the formula -A3-R8 or -A4-X2-A5-R9; A1 and A4, the same or different, each is alkylene; A2, A3 and A5, the same or different, each is a direct link or alkylene; X1 and X2, the same or different, each is oxygen, sulphur, sulphinyl, sulphonyl, imino or alkylimino; R7 and R9, the same or different, each is alkyl, alkenyl, hydroxyalkyl, cycloalkyl, phenyl optionally substituted, naphthyl or heterocyclic optionally substituted; and R8 is phenyl, naphthyl or heterocyclic as defined above for R7 or R9; processes for their manufacture and pharmaceutical compositions containing them. The acylanilides possess antiandrogenic activity.

AU16937/83A
1982-07-23
1983-07-18
Amides

Expired

AU556328B2
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

GB8221421

1982-07-23

GB8221421

1982-07-23

Publications (2)

Publication Number
Publication Date

AU1693783A
true

AU1693783A
(en)

1984-01-26

AU556328B2

AU556328B2
(en)

1986-10-30

Family
ID=10531878
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU16937/83A
Expired

AU556328B2
(en)

1982-07-23
1983-07-18
Amides

Country Status (23)

Country
Link

US
(1)

US4636505A
(en)

EP
(1)

EP0100172B1
(en)

JP
(2)

JPS5933250A
(en)

AT
(1)

ATE28864T1
(en)

AU
(1)

AU556328B2
(en)

CA
(1)

CA1249823A
(en)

CS
(1)

CS399991A3
(en)

DE
(1)

DE3372965D1
(en)

DK
(1)

DK322783D0
(en)

ES
(4)

ES8601106A1
(en)

FI
(1)

FI83770C
(en)

GR
(1)

GR79232B
(en)

HK
(1)

HK92690A
(en)

HU
(1)

HU191296B
(en)

IE
(1)

IE55941B1
(en)

IL
(1)

IL69217A
(en)

LU
(1)

LU88769I2
(en)

MX
(1)

MX9203451A
(en)

NL
(1)

NL950029I2
(en)

NO
(2)

NO164974C
(en)

NZ
(1)

NZ204995A
(en)

PT
(1)

PT77087B
(en)

ZA
(1)

ZA835182B
(en)

Families Citing this family (300)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

JPS54115075A
(en)

*

1978-02-28
1979-09-07
Cho Lsi Gijutsu Kenkyu Kumiai
Plasma etching method

FR2540495B1
(en)

*

1983-02-07
1986-02-14
Roussel Uclaf

NOVEL DERIVATIVES OF O-MERCAPTOPROPANAMIDE AND ITS HOMOLOGUES, THEIR PREPARATION METHOD, THEIR APPLICATION AS MEDICAMENTS, THE COMPOSITIONS CONTAINING THEM AND THE NEW INTERMEDIATES OBTAINED

GB8617653D0
(en)

*

1986-07-18
1986-08-28
Ici Plc
Amide derivatives

GB8617652D0
(en)

*

1986-07-18
1986-08-28
Ici Plc
Acylanilide derivatives

US4921941A
(en)

*

1987-07-01
1990-05-01
Schering Corporation
Orally active antiandrogens

US4970303A
(en)

*

1988-02-03
1990-11-13
Xoma Corporation
Linking agents and methods

US4895715A
(en)

*

1988-04-14
1990-01-23
Schering Corporation
Method of treating gynecomastia

US5204337A
(en)

*

1988-10-31
1993-04-20
Endorecherche Inc.
Estrogen nucleus derivatives for use in inhibition of sex steroid activity

US5364847A
(en)

*

1989-03-10
1994-11-15
Endorecherche
Inhibitors of sex steroid biosynthesis and methods for their production and use

ZA924811B
(en)

*

1991-06-28
1993-12-29
Endorecherche Inc
Controlled release systems and low dose androgens

GB9214120D0
(en)

*

1991-07-25
1992-08-12
Ici Plc
Therapeutic amides

GB9305295D0
(en)

*

1993-03-15
1993-05-05
Zeneca Ltd
Therapeutic compounds

GB9310095D0
(en)

*

1993-05-17
1993-06-30
Zeneca Ltd
Therapeutic compounds

JPH09508125A
(en)

*

1994-01-21
1997-08-19
セプラコー，インコーポレイテッド

Method and composition for the treatment of androgen dependent diseases using optically pure R-(-)-casodex

DE4420777A1
(en)

1994-06-15
1995-12-21
Bayer Ag

Process for the preparation of 4-fluorothiophenol

WO1996000090A1
(en)

*

1994-06-27
1996-01-04
Ionix Corporation
Boron-containing hormone analogs and methods of their use in imaging or killing cells having hormone receptors

US7759520B2
(en)

1996-11-27
2010-07-20
University Of Tennessee Research Foundation
Synthesis of selective androgen receptor modulators

US6071957A
(en)

1996-11-27
2000-06-06
The University Of Tennessee Research Corporation
Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer

US7205437B2
(en)

*

1996-11-27
2007-04-17
University Of Tennessee Research Foundation
Selective androgen receptor modulators

US20090264534A1
(en)

*

1996-11-27
2009-10-22
Dalton James T
Selective androgen receptor modulators

US6995284B2
(en)

2000-08-24
2006-02-07
The University Of Tennessee Research Foundation
Synthesis of selective androgen receptor modulators

US7518013B2
(en)

2000-08-24
2009-04-14
University Of Tennessee Research Foundation
Selective androgen receptor modulators

US20050038110A1
(en)

*

2000-08-24
2005-02-17
Steiner Mitchell S.
Selective androgen receptor modulators and methods of use thereof

AU7604798A
(en)

*

1997-05-30
1998-12-30
University Of Tennessee Research Corporation, The
Non-steroidal agonist compounds and their use in male hormone therapy

US6019957A
(en)

*

1997-06-04
2000-02-01
The University Of Tennessee Research Corporation
Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging

DE19746512A1
(en)

1997-10-22
1999-04-29
Bayer Ag
Preparation of arylmercaptan derivatives

GB9804648D0
(en)

1998-03-06
1998-04-29
Zeneca Ltd
Chemical compounds

GB9805520D0
(en)

1998-03-17
1998-05-13
Zeneca Ltd
Chemical compounds

US20040186185A1
(en)

*

1998-05-07
2004-09-23
Steiner Mitchell S.
Method for treatment and chemoprevention of prostate cancer

GB9811427D0
(en)

1998-05-29
1998-07-22
Zeneca Ltd
Chemical compounds

JP2003525856A
(en)

*

1998-08-28
2003-09-02
スミスクライン・ビーチャム・コーポレイション

Method for producing 2-amino-5-cyanophenol

US6472415B1
(en)

1998-12-18
2002-10-29
Biophysica, Inc.
Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes

US6184249B1
(en)

1998-12-18
2001-02-06
Biophysica, Inc.
Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes

HU223950B1
(en)

*

1999-06-10
2005-03-29
Richter Gedeon Vegyészeti Gyár Rt.
Process for producing racemic and r-(-)- and s-(+)-n-[4-cyano-3-(trifluoromethyl)-phenyl]-3-[(4-fluorophenyl)-sulfonyl]-2-hydroxy-2-methyl-propanecarboxamide

US6566372B1
(en)

*

1999-08-27
2003-05-20
Ligand Pharmaceuticals Incorporated
Bicyclic androgen and progesterone receptor modulator compounds and methods

SK286774B6
(en)

1999-09-04
2009-05-07
Astrazeneca Ab
Substituted N-phenyl-2-hydroxy-2-methyl-3,3,3- trifluoropropanamide derivatives, process for their preparation and pharmaceutical composition comprising the same

US6878712B1
(en)

1999-09-04
2005-04-12
Astrazeneca Ab
Amides as inhibitors for pyruvate dehydrogenase

ES2273725T3
(en)

1999-09-04
2007-05-16
Astrazeneca Ab

HYDROXYACETAMIDOBENCENOSULFONAMIDE DERIVATIVES.

US6713454B1
(en)

*

1999-09-13
2004-03-30
Nobex Corporation
Prodrugs of etoposide and etoposide analogs

US6583306B1
(en)

*

1999-10-19
2003-06-24
Nobex Corporation
Methods of asymmetrically synthesizing enantiomers of Casodex, its derivatives and intermediates thereof

AU2619501A
(en)

*

1999-10-27
2001-06-06
Nobex Corporation
Resolution of intermediates in the synthesis of substantially pure bicalutamide

GB9930839D0
(en)

*

1999-12-30
2000-02-16
Pharmacia & Upjohn Spa
Process for treating gynecomastia

GB0012291D0
(en)

*

2000-05-23
2000-07-12
Astrazeneca Ab
Pharmaceutical combination

GB0012293D0
(en)

*

2000-05-23
2000-07-12
Astrazeneca Ab
Pharmaceutical combination

MY128450A
(en)

2000-05-24
2007-02-28
Upjohn Co
1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives

US6828458B2
(en)

2000-05-25
2004-12-07
Biophysica, Inc.
Topical antiandrogen for hair loss and other hyperandrogenic conditions

GB0016426D0
(en)

*

2000-07-05
2000-08-23
Astrazeneca Ab
Pharmaceutical combination

US7622503B2
(en)

2000-08-24
2009-11-24
University Of Tennessee Research Foundation
Selective androgen receptor modulators and methods of use thereof

US6838484B2
(en)

2000-08-24
2005-01-04
University Of Tennessee Research Foundation
Formulations comprising selective androgen receptor modulators

DK1491524T3
(en)

*

2000-08-24
2009-05-04
Univ Tennessee Res Foundation

Selective androgen receptor modulators and methods for their use

US8008348B2
(en)

2001-12-06
2011-08-30
University Of Tennessee Research Foundation
Treating muscle wasting with selective androgen receptor modulators

US7855229B2
(en)

2000-08-24
2010-12-21
University Of Tennessee Research Foundation
Treating wasting disorders with selective androgen receptor modulators

US8445534B2
(en)

2000-08-24
2013-05-21
University Of Tennessee Research Foundation
Treating androgen decline in aging male (ADAM)-associated conditions with SARMs

US20040260108A1
(en)

*

2001-06-25
2004-12-23
Dalton James T.
Metabolites of selective androgen receptor modulators and methods of use thereof

US20070173546A1
(en)

*

2000-08-24
2007-07-26
Dalton James T
Selective androgen receptor modulators and method of use thereof

US7919647B2
(en)

2000-08-24
2011-04-05
University Of Tennessee Research Foundation
Selective androgen receptor modulators and methods of use thereof

US7026500B2
(en)

*

2000-08-24
2006-04-11
University Of Tennessee Research Foundation
Halogenated selective androgen receptor modulators and methods of use thereof

US7645898B2
(en)

2000-08-24
2010-01-12
University Of Tennessee Research Foundation
Selective androgen receptor modulators and method of use thereof

US6998500B2
(en)

2000-08-24
2006-02-14
University Of Tennessee Research Foundation
Selective androgen receptor modulators and methods of use thereof

US20030232792A1
(en)

*

2000-08-24
2003-12-18
Dalton James T.
Selective androgen receptor modulators and methods of use thereof

IL154425A0
(en)

2000-08-24
2003-09-17
Univ Tennessee Res H Corp
Selective androgen receptor modulators and methods of use thereof

HU0302930A3
(en)

*

2000-09-21
2006-02-28
Bristol Myers Squibb Co
Process for the preparation n-(substituted phenyl)-3-alkyl-,aryl- and heteroaryl-sulfonil-2-hydroxy-2-alkyl- and haloalkylpropanamide compounds

ES2600304T3
(en)

2001-02-19
2017-02-08
Novartis Ag

Treatment of solid kidney tumors with a rapamycin derivative

JP3548566B2
(en)

*

2001-02-27
2004-07-28
アストラゼネカ アクチボラグ

Pharmaceutical preparations

US6479692B1
(en)

*

2001-05-02
2002-11-12
Nobex Corporation
Methods of synthesizing acylanilides including bicalutamide and derivatives thereof

EP2253319A1
(en)

2001-05-16
2010-11-24
Novartis AG
Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent.

EP1406855A4
(en)

*

2001-06-13
2006-04-19
Teva Gyogyszergyar Reszvenytar
Novel process for preparing rac-bicalutamide and its intermediates

US7102026B2
(en)

*

2001-06-13
2006-09-05
Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság
Process for preparing and isolating rac-bicalutamide and its intermediates

US20060287282A1
(en)

*

2001-06-25
2006-12-21
Steiner Mitchell S
Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof

AU2002322493A1
(en)

*

2001-07-10
2003-01-29
Ams Research Corporation
Surgical kit for treating prostate tissue

US20060004042A1
(en)

*

2001-08-23
2006-01-05
Dalton James T
Formulations comprising selective androgen receptor modulators

SE0103424D0
(en)

*

2001-10-15
2001-10-15
Astrazeneca Ab

Pharmaceutical formulation

AT410545B
(en)

*

2001-11-07
2003-05-26
Dsm Fine Chem Austria Gmbh

METHOD FOR PRODUCING CHIRAL ALPHA HYDROXYCARBOXYLIC ACIDS

GB0128510D0
(en)

*

2001-11-28
2002-01-23
Novartis Ag
Organic compounds

US20070161608A1
(en)

*

2001-12-06
2007-07-12
Dalton James T
Selective androgen receptor modulators for treating muscle wasting

WO2003049675A2
(en)

*

2001-12-06
2003-06-19
Gtx, Inc.
Treating muscle wasting with selective androgen receptor modulators

US8853266B2
(en)

2001-12-06
2014-10-07
University Of Tennessee Research Foundation
Selective androgen receptor modulators for treating diabetes

AU2002354475B2
(en)

2001-12-13
2008-08-14
Sumitomo Chemical Company, Limited
Crystals of bicalutamide and process for their production

EA200901492A1
(en)

*

2002-02-07
2010-08-30
Юниверсити Оф Теннесси Рисерч Фаундейшн

Treatment of benign prostatic hyperplasia by the selective modulator of the androgen receptor (sarm)

KR20040088519A
(en)

2002-02-22
2004-10-16
뉴 리버 파마슈티칼스, 인크.
Active Agent Delivery Systems and Methods for Protecting and Administering Active Agents

MXPA04008413A
(en)

*

2002-02-28
2005-06-08
Univ Tennessee Res Corp
Haloacetamide and azide substituted compounds and methods of use thereof.

US7803970B2
(en)

2002-02-28
2010-09-28
University Of Tennessee Research Foundation
Multi-substitued selective androgen receptor modulators and methods of use thereof

US7772433B2
(en)

2002-02-28
2010-08-10
University Of Tennessee Research Foundation
SARMS and method of use thereof

ES2528764T3
(en)

*

2002-02-28
2015-02-12
University Of Tennessee Research Foundation

Multi-substituted selective androgen receptor modulators and methods of use thereof

AU2003217304A1
(en)

2002-02-28
2003-09-16
The University Of Tennessee Research Corporation
Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy

GB0206215D0
(en)

2002-03-15
2002-05-01
Novartis Ag
Organic compounds

NZ536513A
(en)

2002-05-16
2007-10-26
Novartis Ag
Use of EDG receptor binding agents in cancer

US7741371B2
(en)

2002-06-17
2010-06-22
University Of Tennessee Research Foundation
Selective androgen receptor modulators and methods of use thereof

KR20050010059A
(en)

2002-06-17
2005-01-26
유니버시티 오브 테네시 리서치 파운데이션
N-bridged selective androgen receptor modulators and methods of use thereof

DK1557411T3
(en)

2002-07-12
2012-11-05
Astellas Pharma Inc

N-phenyl- (2R, 5S) -DIMETHYLPIPERAZIN DERIVATIVE

US20040063782A1
(en)

*

2002-09-27
2004-04-01
Westheim Raymond J.H.
Bicalutamide forms

US6818766B2
(en)

*

2002-10-02
2004-11-16
Synthon Bv
Process for making bicalutamide and intermediates thereof

EP1562906A4
(en)

*

2002-10-15
2009-12-02
Univ Tennessee Res Foundation
Heterocyclic selective androgen receptor modulators and methods of use thereof

WO2004034978A2
(en)

*

2002-10-15
2004-04-29
Gtx, Inc.
Treating obesity with selective androgen receptor modulators

JP2006506369A
(en)

*

2002-10-15
2006-02-23
ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション

Methylene bridge selective androgen receptor modulator and method of use thereof

US20040197928A1
(en)

*

2002-10-15
2004-10-07
Dalton James T.
Method for detecting selective androgen receptor modulators

US20060276539A1
(en)

*

2002-10-16
2006-12-07
Dalton James T
Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS

CA2501874A1
(en)

*

2002-10-16
2004-04-29
Gtx, Inc.
Treating androgen decline in aging male (adam)-associated conditions with sarms

US20040087810A1
(en)

*

2002-10-23
2004-05-06
Dalton James T.
Irreversible selective androgen receptor modulators and methods of use thereof

PL201541B1
(en)

*

2002-10-30
2009-04-30
Inst Farmaceutyczny
Method of manufacture of N-(4-cyano-3-trifluoromethylo phenylo)-2,3-epoxy-2-methyl prop anamide

PL201540B1
(en)

*

2002-10-30
2009-04-30
Inst Farmaceutyczny
Method of manufacture of high purity N-(4-cyano-3-trifluoromethyl phenylo)-3-(4-fluorophenylosulfon ylo)-2-hydroxy-2- methyl propane amide

US8309603B2
(en)

2004-06-07
2012-11-13
University Of Tennessee Research Foundation
SARMs and method of use thereof

AU2004204800B8
(en)

2003-01-13
2011-05-26
University Of Tennessee Research Foundation
Large-scale synthesis of selective androgen receptor modulators

US7332525B2
(en)

*

2003-01-17
2008-02-19
Castle Erik P
Method of treatment of prostate cancer and composition for treatment thereof

AU2003209667A1
(en)

*

2003-02-21
2004-09-09
Hetero Drugs Limited
Bicalutamide polymorphs

US20040167103A1
(en)

*

2003-02-24
2004-08-26
Dalton James T.
Haloacetamide and azide substituted compounds and methods of use thereof

US7709525B2
(en)

2003-02-27
2010-05-04
Wisconsin Alumni Research Foundation
Chroman-derived anti-androgens for treatment of androgen-mediated disorders

US20050008691A1
(en)

*

2003-05-14
2005-01-13
Arturo Siles Ortega
Bicalutamide compositions

WO2005009946A1
(en)

*

2003-06-25
2005-02-03
TEVA Gyógyszergyár Részvénytársaság
Process for purifying and isolating rac-bicalutamide

CN100462353C
(en)

*

2003-06-27
2009-02-18
奥赖恩公司
Propionamide derivatives useful as androgen receptor modulators

FI20030958A0
(en)

*

2003-06-27
2003-06-27
Orion Corp

New compounds

MXPA05013619A
(en)

*

2003-06-27
2006-03-10
Orion Corp
Propionamide derivatives useful as androgen receptor modulators.

EP1651612B9
(en)

2003-07-22
2012-09-05
Astex Therapeutics Limited
3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators

JP2005060302A
(en)

*

2003-08-12
2005-03-10
Sumitomo Chemical Co Ltd
Method for producing n-methacryloyl-4-cyano-3-trifluoromethylaniline and method for stabilizing the same

CA2536349A1
(en)

2003-08-22
2005-03-03
Ligand Pharmaceuticals Incorporated
6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds

CN101721402B
(en)

*

2003-10-14
2013-03-13
田纳西大学研究基金会
Treating bone-related disorders with selective androgen receptor modulators

TW200523235A
(en)

*

2003-10-15
2005-07-16
Gtx Inc
Anti-cancer compounds and methods of use thereof

BRPI0416639A
(en)

2003-11-19
2007-01-16
Metabasis Therapeutics Inc

phosphorus-containing thyromimetics

EA200501761A1
(en)

2003-12-16
2006-04-28
Джи Ти Икс, ИНК.

PROTECTIVE FORMS OF SELECTIVE MODULATORS OF ANDROGEN RECEPTORS AND METHODS OF THEIR APPLICATION

US20050250709A1
(en)

*

2003-12-19
2005-11-10
Bionaut Pharmaceuticals
Anti-neoplastic agents, combination therapies and related methods

KR100783255B1
(en)

2004-02-13
2007-12-06
워너-램버트 캄파니 엘엘씨
Androgen receptor modulators

US8519158B2
(en)

2004-03-12
2013-08-27
Ligand Pharmaceuticals Incorporated
Androgen receptor modulator compounds and methods

PE20110102A1
(en)

2004-04-07
2011-02-07
Novartis Ag

DERIVATIVES OF N- (2-OXO-2-PYRROLIDINYL-1-IL) ETHYL-2-AMINO-ACETAMIDE AS INHIBITORS OF APOPTOSIS PROTEINS (IAP)

US7507860B2
(en)

2004-04-13
2009-03-24
Pfizer Inc.
Androgen modulators

BRPI0509980A
(en)

2004-04-22
2007-10-16
Warner Lambert Co

androgen modulators

US9884038B2
(en)

2004-06-07
2018-02-06
University Of Tennessee Research Foundation
Selective androgen receptor modulator and methods of use thereof

US20110237664A1
(en)

*

2004-06-07
2011-09-29
Dalton James T
Selective androgen receptor modulators for treating diabetes

US9889110B2
(en)

2004-06-07
2018-02-13
University Of Tennessee Research Foundation
Selective androgen receptor modulator for treating hormone-related conditions

CA2543827C
(en)

*

2004-06-07
2010-03-09
James T. Dalton
Selective androgen receptor modulators and methods of use thereof

ITMI20041222A1
(en)

*

2004-06-17
2004-09-17
Cosma S P A

PROCESS PERFECTED FOR THE SYNTHESIS OF BICALUTAMIDE

GB0512324D0
(en)

2005-06-16
2005-07-27
Novartis Ag
Organic compounds

CA2570047C
(en)

2004-07-08
2010-09-28
Warner-Lambert Company Llc
4-cycloalkoxy benzonitriles as androgen modulators

ATE521590T1
(en)

2004-07-14
2011-09-15
Sumitomo Chemical Co

METHOD FOR CRYSTALLIZATION OF BICALUTAMID

US20060258628A1
(en)

*

2004-07-20
2006-11-16
Steiner Mitchell S
Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof

US20080027010A1
(en)

*

2004-09-02
2008-01-31
Bionaut Pharmaceuticals, Inc.
Treatment of refractory cancers using Na+/K+-ATPase inhibitors

US20060135468A1
(en)

*

2004-09-02
2006-06-22
Bionaut Pharmaceuticals, Inc.
Treatment of refractory cancers using NA+/K+ ATPase inhibitors

EP1789090A2
(en)

*

2004-09-02
2007-05-30
Bionaut Pharmaceuticals, Inc.
Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors

US20070105790A1
(en)

*

2004-09-02
2007-05-10
Bionaut Pharmaceuticals, Inc.
Pancreatic cancer treatment using Na+/K+ ATPase inhibitors

WO2006028969A1
(en)

*

2004-09-02
2006-03-16
Bionaut Pharmaceuticals, Inc.
Pancreatic cancer treatment using na+/k+ atpase inhibitors

US20060135443A1
(en)

*

2004-10-18
2006-06-22
Bionaut Pharmaceuticals, Inc.
Use of Na*/K*-ATPase inhibitors and antagonists thereof

US20060159767A1
(en)

*

2004-12-22
2006-07-20
Elan Pharma International Limited
Nanoparticulate bicalutamide formulations

US8404718B2
(en)

2005-01-21
2013-03-26
Astex Therapeutics Limited
Combinations of pyrazole kinase inhibitors

US20090036435A1
(en)

2005-01-21
2009-02-05
Astex Therapeutics Limited
Pharmaceutical Compounds

AR054425A1
(en)

2005-01-21
2007-06-27
Astex Therapeutics Ltd

PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.

JP2008534575A
(en)

*

2005-03-29
2008-08-28
ユーエスヴィー リミテッド

A new process for the preparation of bicalutamide

TW200724139A
(en)

2005-05-05
2007-07-01
Warner Lambert Co
Androgen modulators

US7709517B2
(en)

*

2005-05-13
2010-05-04
The Regents Of The University Of California
Diarylhydantoin compounds

GB0510390D0
(en)

2005-05-20
2005-06-29
Novartis Ag
Organic compounds

US7709516B2
(en)

2005-06-17
2010-05-04
Endorecherche, Inc.
Helix 12 directed non-steroidal antiandrogens

BRPI0609191B8
(en)

*

2005-06-17
2021-05-25
Ligand Pharm Inc

androgen receptor modulating methods and compounds

CA2513356A1
(en)

*

2005-07-26
2007-01-26
Apotex Pharmachem Inc.
Process for production of bicalutamide

AR058065A1
(en)

2005-09-27
2008-01-23
Novartis Ag

CARBOXYAMINE COMPOUNDS AND USE OF THE SAME PHARMACEUTICAL COMPOSITIONS.

US7741317B2
(en)

2005-10-21
2010-06-22
Bristol-Myers Squibb Company
LXR modulators

EP1954269A2
(en)

2005-11-21
2008-08-13
Novartis AG
Neuroendocrine tumor treatment using mtor inhibitors

US7888376B2
(en)

2005-11-23
2011-02-15
Bristol-Myers Squibb Company
Heterocyclic CETP inhibitors

WO2007074473A1
(en)

*

2005-12-27
2007-07-05
Dabur Pharma Limited
An improved process for preparation of bicalutamide

AU2007220419B2
(en)

*

2006-03-03
2012-03-15
Orion Corporation
Selective androgen receptor modulators

GB0605120D0
(en)

2006-03-14
2006-04-26
Novartis Ag
Organic Compounds

SG170809A1
(en)

2006-03-29
2011-05-30
Univ California
Diarylthiohydantoin compounds

KR20080108517A
(en)

2006-04-05
2008-12-15
노파르티스 아게
Combinations of therapeutic agents for treating cancer

KR20080109068A
(en)

2006-04-05
2008-12-16
노파르티스 아게
Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer

AU2007247112B2
(en)

2006-05-09
2010-08-26
Novartis Ag
Combination comprising an iron chelator and an anti-neoplastic agent and use thereof

WO2008013791A2
(en)

*

2006-07-24
2008-01-31
University Of Delaware
Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal

US9730908B2
(en)

2006-08-24
2017-08-15
University Of Tennessee Research Foundation
SARMs and method of use thereof

US9844528B2
(en)

2006-08-24
2017-12-19
University Of Tennessee Research Foundation
SARMs and method of use thereof

BRPI0714526A2
(en)

2006-08-24
2013-04-30
Univ Tennessee Res Foundation

substituted acylanilides and their methods of use

US10010521B2
(en)

2006-08-24
2018-07-03
University Of Tennessee Research Foundation
SARMs and method of use thereof

AU2007302263A1
(en)

2006-09-29
2008-04-03
Novartis Ag
Pyrazolopyrimidines as P13K lipid kinase inhibitors

WO2008044033A1
(en)

*

2006-10-11
2008-04-17
Astrazeneca Ab
Amide derivatives

JP5528807B2
(en)

2006-10-12
2014-06-25
アステックス、セラピューティックス、リミテッド

Compound drug

EP2073803B1
(en)

2006-10-12
2018-09-19
Astex Therapeutics Limited
Pharmaceutical combinations

EP2094643B1
(en)

2006-12-01
2012-02-29
Bristol-Myers Squibb Company
N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases

ES2858596T3
(en)

2007-01-02
2021-09-30
Aquabeam Llc

Minimally invasive devices for the treatment of prostate diseases

US9232959B2
(en)

2007-01-02
2016-01-12
Aquabeam, Llc
Multi fluid tissue resection methods and devices

CN101626758A
(en)

2007-02-15
2010-01-13
诺瓦提斯公司
Combinations of therapeutic agents for treating cancer

US20080245375A1
(en)

*

2007-04-05
2008-10-09
Medtronic Vascular, Inc.
Benign Prostatic Hyperplasia Treatments

US9284345B2
(en)

2007-04-12
2016-03-15
Endorecherche, Inc.
17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators

US8110550B2
(en)

2007-06-06
2012-02-07
University Of Maryland, Baltimore
HDAC inhibitors and hormone targeted drugs for the treatment of cancer

US7968603B2
(en)

2007-09-11
2011-06-28
University Of Tennessee Research Foundation
Solid forms of selective androgen receptor modulators

US20090076158A1
(en)

*

2007-09-13
2009-03-19
Protia, Llc
Deuterium-enriched bicalutamide

CA2966280A1
(en)

2007-10-26
2009-04-30
The Regents Of The University Of California
Diarylhydantoin compounds

EP3622910A1
(en)

2008-03-06
2020-03-18
AquaBeam LLC
Tissue ablation and cautery with optical energy carried in fluid stream

US8222424B2
(en)

2008-03-24
2012-07-17
Novartis Ag
Arylsulfonamide-based matrix metalloprotease inhibitors

CA2719477C
(en)

2008-03-26
2016-11-08
Novartis Ag
Hydroxamate-based inhibitors of deacetylases b

WO2010083617A1
(en)

2009-01-21
2010-07-29
Oncalis Ag
Pyrazolopyrimidines as protein kinase inhibitors

ES2396023T3
(en)

2009-01-29
2013-02-18
Novartis Ag

Substituted benzimidazoles for the treatment of astrocytomas

WO2010093601A1
(en)

2009-02-10
2010-08-19
Metabasis Therapeutics, Inc.
Novel sulfonic acid-containing thyromimetics, and methods for their use

US9848904B2
(en)

2009-03-06
2017-12-26
Procept Biorobotics Corporation
Tissue resection and treatment with shedding pulses

WO2010116342A2
(en)

*

2009-04-10
2010-10-14
Consiglio Nazionale Delle Ricerche
Non-steroidal compounds for androgen receptor modulation

ITBO20090235A1
(en)

*

2009-04-10
2010-10-11
Consiglio Nazionale Ricerche

COMPOUNDS FOR TREATING TUMOR TO THE PROSTATE AND PROCEDURES FOR THEIR SYNTHESIS

NZ596488A
(en)

2009-06-26
2012-11-30
Novartis Ag
1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17

WO2011008543A2
(en)

*

2009-06-29
2011-01-20
University Of Delaware
Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal

US8389526B2
(en)

2009-08-07
2013-03-05
Novartis Ag
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives

EP2464649A1
(en)

2009-08-12
2012-06-20
Novartis AG
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation

AU2010284972A1
(en)

2009-08-20
2012-03-08
Novartis Ag
Heterocyclic oxime compounds

CA2771936A1
(en)

2009-08-26
2011-03-03
Novartis Ag
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators

EP2475668A1
(en)

2009-09-10
2012-07-18
Novartis AG
Ether derivatives of bicyclic heteroaryls

AR078793A1
(en)

2009-10-27
2011-12-07
Orion Corp

DERIVATIVES OF NON-STEROID CARBOXAMIDS AND ACIL HYDRAZONE MODULATORS OF ANDROGENIC RECEPTORS OF SELECTIVE FABRIC (SARM), PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME IN THE TREATMENT OF PROSTATE CANCER BETWEEN OTHERS

EA201200651A1
(en)

2009-11-04
2012-12-28
Новартис Аг

HETEROCYCLIC SULPHONAMIDE DERIVATIVES APPLICABLE AS MEK INHIBITORS

CN102712648A
(en)

2009-11-25
2012-10-03
诺瓦提斯公司
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls

WO2011064663A1
(en)

2009-11-25
2011-06-03
Festuccia, Claudio
Combination treatment employing belinostat and bicalutamide

JP5456908B2
(en)

2009-12-08
2014-04-02
ノバルティス アーゲー

Heterocyclic sulfonamide derivatives

US8440693B2
(en)

2009-12-22
2013-05-14
Novartis Ag
Substituted isoquinolinones and quinazolinones

CU24130B1
(en)

2009-12-22
2015-09-29
Novartis Ag

ISOQUINOLINONES AND REPLACED QUINAZOLINONES

CN101759597B
(en)

*

2009-12-31
2013-09-04
上海康鹏化学有限公司
Preparation method of 2-trifluoromethyl-4-aminobenzonitrile

US8791158B2
(en)

*

2010-01-11
2014-07-29
Gtx, Inc.
Methods of treating meibomian gland dysfunction

US20130090342A1
(en)

2010-06-17
2013-04-11
Novartis Ag
Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives

US20130085161A1
(en)

2010-06-17
2013-04-04
Novartis Ag
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives

UA112517C2
(en)

2010-07-06
2016-09-26
Новартіс Аг

TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES

FI20105806A0
(en)

2010-07-15
2010-07-15
Medeia Therapeutics Ltd

New arylamide derivatives with antiandrogenic properties

WO2012035078A1
(en)

2010-09-16
2012-03-22
Novartis Ag
17α-HYDROXYLASE/C17,20-LYASE INHIBITORS

US8895772B2
(en)

2010-09-29
2014-11-25
Shilpa Medicare Limited
Process for preparing bicalutamide

WO2012109387A1
(en)

2011-02-08
2012-08-16
Halozyme, Inc.
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia

EP2673277A1
(en)

2011-02-10
2013-12-18
Novartis AG
[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase

WO2012120469A1
(en)

2011-03-08
2012-09-13
Novartis Ag
Fluorophenyl bicyclic heteroaryl compounds

JP5964407B2
(en)

2011-04-21
2016-08-03
オリオン コーポレーション

Androgen receptor modulating carboxamide

WO2012149413A1
(en)

2011-04-28
2012-11-01
Novartis Ag
17α-HYDROXYLASE/C17,20-LYASE INHIBITORS

CN103596935A
(en)

2011-05-16
2014-02-19
建新公司
Use of cxcr4 antagonists

EA201391820A1
(en)

2011-06-09
2014-12-30
Новартис Аг

HETEROCYCLIC SULPHONAMIDE DERIVATIVES

WO2012175520A1
(en)

2011-06-20
2012-12-27
Novartis Ag
Hydroxy substituted isoquinolinone derivatives

WO2012175487A1
(en)

2011-06-20
2012-12-27
Novartis Ag
Cyclohexyl isoquinolinone compounds

MX2013015001A
(en)

2011-06-27
2014-03-31
Novartis Ag
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives.

WO2013038362A1
(en)

2011-09-15
2013-03-21
Novartis Ag
6 – substituted 3 – (quinolin- 6 – ylthio) – [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase

CN104080787B
(en)

2011-11-29
2016-09-14
诺华股份有限公司
Pyrazolo pyrrolidine compound

PT2785349T
(en)

2011-11-30
2019-12-11
Astrazeneca Ab
Combination treatment of cancer

WO2013093850A1
(en)

2011-12-22
2013-06-27
Novartis Ag
Quinoline derivatives

CR20200286A
(en)

2011-12-22
2020-09-23
Novartis Ag
Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives

CA2859876A1
(en)

2011-12-23
2013-06-27
Novartis Ag
Compounds for inhibiting the interaction of bcl2 with binding partners

EP2794590A1
(en)

2011-12-23
2014-10-29
Novartis AG
Compounds for inhibiting the interaction of bcl2 with binding partners

AU2012355623A1
(en)

2011-12-23
2014-07-17
Novartis Ag
Compounds for inhibiting the interaction of BCL2 with binding partners

AU2012355613A1
(en)

2011-12-23
2014-07-17
Novartis Ag
Compounds for inhibiting the interaction of BCL2 with binding partners

AU2012355615A1
(en)

2011-12-23
2014-07-10
Novartis Ag
Compounds for inhibiting the interaction of BCL2 with binding partners

WO2013104831A1
(en)

2012-01-13
2013-07-18
Medeia Therapeutics Ltd
Arylamide derivatives having antiandrogenic properties

WO2013104829A1
(en)

2012-01-13
2013-07-18
Medeia Therapeutics Ltd
Novel arylamide derivatives having antiandrogenic properties

AU2013208847B2
(en)

2012-01-13
2017-08-31
Aranda Pharma Ltd
Novel heteroarylamide derivatives having antiandrogenic properties

UY34591A
(en)

2012-01-26
2013-09-02
Novartis Ag

IMIDAZOPIRROLIDINONA COMPOUNDS

CN104203078B
(en)

2012-02-29
2018-04-20
普罗赛普特生物机器人公司
The cutting tissue of automated image guiding and processing

WO2013149581A1
(en)

2012-04-03
2013-10-10
Novartis Ag
Combination products with tyrosine kinase inhibitors and their use

WO2013152170A1
(en)

2012-04-04
2013-10-10
Catylix, Inc.
Selective androgen receptor modulators

AU2013204533B2
(en)

2012-04-17
2017-02-02
Astrazeneca Ab
Crystalline forms

UY34807A
(en)

2012-05-16
2013-12-31
Novartis Ag

MONOCYCLIC DERIVATIVES OF HETEROARYL CYCLOALKYL-DIAMINE

JP6171003B2
(en)

2012-05-24
2017-07-26
ノバルティス アーゲー

Pyrrolopyrrolidinone compounds

ES2818915T3
(en)

2012-07-13
2021-04-14
Oncternal Therapeutics Inc

Method of treating breast cancers with a selective androgen receptor modulator (SARM)

US10987334B2
(en)

2012-07-13
2021-04-27
University Of Tennessee Research Foundation
Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)

US9969683B2
(en)

2012-07-13
2018-05-15
Gtx, Inc.
Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)

US9744149B2
(en)

2012-07-13
2017-08-29
Gtx, Inc.
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)

US9622992B2
(en)

2012-07-13
2017-04-18
Gtx, Inc.
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)

US10314807B2
(en)

2012-07-13
2019-06-11
Gtx, Inc.
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)

US10258596B2
(en)

2012-07-13
2019-04-16
Gtx, Inc.
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)

IN2015DN00950A
(en)

2012-08-13
2015-06-12
Novartis Ag

KR102160320B1
(en)

2012-10-02
2020-09-28
에피테라퓨틱스 에이피에스
Inhibitors of histone demethylases

TW201422625A
(en)

2012-11-26
2014-06-16
Novartis Ag
Solid form of dihydro-pyrido-oxazine derivative

RU2510392C1
(en)

*

2012-12-21
2014-03-27
Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской академии наук (ИХР РАН)
Co-crystalline form of bicalutamide

US9556180B2
(en)

2013-01-22
2017-01-31
Novartis Ag
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction

US9403827B2
(en)

2013-01-22
2016-08-02
Novartis Ag
Substituted purinone compounds

JP6403695B2
(en)

2013-02-14
2018-10-10
プロセプト バイオロボティクス コーポレイション

Aqua ablation aqua beam ophthalmic surgery method and apparatus

WO2014128612A1
(en)

2013-02-20
2014-08-28
Novartis Ag
Quinazolin-4-one derivatives

SG10201707027SA
(en)

2013-02-27
2017-09-28
Epitherapeutics Aps
Inhibitors of histone demethylases

WO2014155268A2
(en)

2013-03-25
2014-10-02
Novartis Ag
Fgf-r tyrosine kinase activity inhibitors – use in diseases associated with lack of or reduced snf5 activity

US20150018376A1
(en)

2013-05-17
2015-01-15
Novartis Ag
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof

UY35675A
(en)

2013-07-24
2015-02-27
Novartis Ag

SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA

US9227969B2
(en)

2013-08-14
2016-01-05
Novartis Ag
Compounds and compositions as inhibitors of MEK

WO2015022664A1
(en)

2013-08-14
2015-02-19
Novartis Ag
Compounds and compositions as inhibitors of mek

WO2015022663A1
(en)

2013-08-14
2015-02-19
Novartis Ag
Compounds and compositions as inhibitors of mek

CN109965976B
(en)

2013-09-06
2022-05-31
普罗赛普特生物机器人公司
Device for ablating tissue using ablation pulses

KR20160058889A
(en)

2013-09-22
2016-05-25
칼리토르 사이언시즈, 엘엘씨
Substituted aminopyrimidine compounds and methods of use

WO2015084804A1
(en)

2013-12-03
2015-06-11
Novartis Ag
Combination of mdm2 inhibitor and braf inhibitor and their use

US9682960B2
(en)

2013-12-19
2017-06-20
Endorecherche, Inc.
Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety

CN103772238B
(en)

*

2014-01-24
2017-03-22
苏州伊莱特新药研发有限公司
Novel ester group-containing aromatic propionamide compound as well as preparation method and application thereof

WO2015148869A1
(en)

2014-03-28
2015-10-01
Calitor Sciences, Llc
Substituted heteroaryl compounds and methods of use

AR099890A1
(en)

2014-03-31
2016-08-24
Epitherapeutics Aps

HISTONE DEMETILASE INHIBITORS

WO2015196144A2
(en)

2014-06-20
2015-12-23
England Pamela M
Androgen receptor antagonists

EP3160367B1
(en)

2014-06-30
2022-07-13
PROCEPT BioRobotics Corporation
Fluid jet tissue resection and cold coagulation (aquablation) apparatus

CN104151197B
(en)

*

2014-07-25
2017-02-22
苏州伊莱特新药研发有限公司
Aromatic amide compound as well as preparation method and application thereof

WO2016011658A1
(en)

2014-07-25
2016-01-28
Novartis Ag
Combination therapy

JP6526789B2
(en)

2014-07-31
2019-06-05
ノバルティス アーゲー

Combination therapy

WO2016033169A1
(en)

2014-08-27
2016-03-03
Epitherapeutics Aps
Compounds and methods for inhibiting histone demethylases

CN107072591B
(en)

2014-09-05
2021-10-26
普罗赛普特生物机器人公司
Physician-controlled tissue ablation in conjunction with treatment mapping of target organ images

WO2016079521A1
(en)

2014-11-20
2016-05-26
University College Cardiff Consultants Limited
Androgen receptor modulators and their use as anti-cancer agents

WO2016079522A1
(en)

2014-11-20
2016-05-26
University College Cardiff Consultants Limited
Androgen receptor modulators and their use as anti-cancer agents

JP6786520B2
(en)

2015-04-21
2020-11-18
ジーティーエックス・インコーポレイテッド

Selective androgen receptor degradation agent (SARD) ligand and how to use it

US10017471B2
(en)

2015-04-21
2018-07-10
University Of Tennessee Research Foundation
Selective androgen receptor degrader (SARD) ligands and methods of use thereof

US10441570B2
(en)

2015-04-21
2019-10-15
University Of Tennessee Research Foundation
Selective androgen receptor degrader (SARD) Ligands and methods of use thereof

US10035763B2
(en)

2015-04-21
2018-07-31
Gtx, Inc.
Selective androgen receptor degrader (SARD) ligands and methods of use thereof

EP3285757B1
(en)

2015-04-21
2021-09-22
Oncternal Therapeutics, Inc.
Selective androgen receptor degrader (sard) ligands and methods of use thereof

US10865184B2
(en)

2015-04-21
2020-12-15
University Of Tennessee Research Foundation
Selective androgen receptor degrader (SARD) ligands and methods of use thereof

US10806720B2
(en)

2015-04-21
2020-10-20
University Of Tennessee Research Foundation
Selective androgen receptor degrader (SARD) ligands and methods of use thereof

US9834507B2
(en)

2015-04-21
2017-12-05
University Of Tennessee Research Foundation
Selective androgen receptor degrader (SARD) ligands and methods of use thereof

US10093613B2
(en)

2015-04-21
2018-10-09
Gtx, Inc.
Selective androgen receptor degrader (SARD) ligands and methods of use thereof

US10654809B2
(en)

2016-06-10
2020-05-19
University Of Tennessee Research Foundation
Selective androgen receptor degrader (SARD) ligands and methods of use thereof

JP2018527362A
(en)

2015-09-11
2018-09-20
サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ．

Substituted heteroaryl compounds and methods of use

US11230523B2
(en)

2016-06-10
2022-01-25
University Of Tennessee Research Foundation
Selective androgen receptor degrader (SARD) ligands and methods of use thereof

CN106748884B
(en)

*

2016-12-13
2021-08-20
山西振东制药股份有限公司
Preparation method of bicalutamide intermediate

WO2019099311A1
(en)

2017-11-19
2019-05-23
Sunshine Lake Pharma Co., Ltd.
Substituted heteroaryl compounds and methods of use

JP7021356B2
(en)

2017-12-21
2022-02-16
ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ

Pyrimidine derivative kinase inhibitors

US10751339B2
(en)

2018-01-20
2020-08-25
Sunshine Lake Pharma Co., Ltd.
Substituted aminopyrimidine compounds and methods of use

US20210386826A1
(en)

2018-11-05
2021-12-16
Pfizer Inc.
Combination for Treating Cancer

CN109438297B
(en)

*

2018-12-03
2021-05-14
昆明积大制药股份有限公司
Androgen receptor antagonist, preparation method and application thereof

EP4196126A1
(en)

2020-08-13
2023-06-21
Pfizer Inc.
Combination therapy

WO2022200982A1
(en)

2021-03-24
2022-09-29
Pfizer Inc.
Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US3133119A
(en)

*

1961-11-09
1964-05-12
Givaudan Corp
Substituted acetanilides and propionanilides

US3995060A
(en)

*

1972-06-20
1976-11-30
Schering Corporation
Antiandrogenic agents and method for the treatment of androgen dependent disease states

CH493198A
(en)

*

1968-05-06
1970-07-15
Ciba Geigy

Pesticides

FR2142803A1
(en)

*

1971-06-25
1973-02-02
Scherico Ltd
3,4-disubstd anilides – having antiandrogenic activity

US3875229A
(en)

*

1972-11-24
1975-04-01
Schering Corp
Substituted carboxanilides

US4144270A
(en)

*

1973-04-19
1979-03-13
Schering Corporation
Substituted anilides as anti-androgens

US4329364A
(en)

*

1974-09-11
1982-05-11
Schering Corporation
Antiandrogenic agents and methods for the treatment of androgen dependent disease states

US4039684A
(en)

*

1976-03-25
1977-08-02
Schering Corporation
Method for treatment of canine seborrhea

JPS6044294B2
(en)

*

1976-04-15
1985-10-02
帝国臓器製薬株式会社

Anilide derivative

US4139638A
(en)

*

1976-09-23
1979-02-13
Schering Corporation
Methods for the treatment of hirsutism

EP0002309B1
(en)

*

1977-10-12
1982-12-01
Imperial Chemical Industries Plc
Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them

US4191775A
(en)

*

1977-12-15
1980-03-04
Imperial Chemical Industries Limited
Amide derivatives

NZ197008A
(en)

*

1980-05-22
1984-10-19
Ici Ltd
Acylanilide derivatives and pharmaceutical compositions

1983

1983-07-08
AT
AT83303998T
patent/ATE28864T1/en
active

1983-07-08
DE
DE8383303998T
patent/DE3372965D1/en
not_active
Expired

1983-07-08
LU
LU88769C
patent/LU88769I2/en
unknown

1983-07-08
EP
EP83303998A
patent/EP0100172B1/en
not_active
Expired

1983-07-12
GR
GR71917A
patent/GR79232B/el
unknown

1983-07-13
IL
IL69217A
patent/IL69217A/en
not_active
IP Right Cessation

1983-07-13
DK
DK3227/83A
patent/DK322783D0/en
not_active
Application Discontinuation

1983-07-15
ZA
ZA835182A
patent/ZA835182B/en
unknown

1983-07-15
US
US06/514,332
patent/US4636505A/en
not_active
Expired – Lifetime

1983-07-18
HU
HU832531A
patent/HU191296B/en
unknown

1983-07-18
NO
NO832599A
patent/NO164974C/en
not_active
IP Right Cessation

1983-07-18
AU
AU16937/83A
patent/AU556328B2/en
not_active
Expired

1983-07-20
JP
JP58131085A
patent/JPS5933250A/en
active
Granted

1983-07-20
FI
FI832644A
patent/FI83770C/en
not_active
IP Right Cessation

1983-07-20
CA
CA000432811A
patent/CA1249823A/en
not_active
Expired

1983-07-22
NZ
NZ204995A
patent/NZ204995A/en
unknown

1983-07-22
IE
IE1732/83A
patent/IE55941B1/en
not_active
IP Right Cessation

1983-07-22
ES
ES524392A
patent/ES8601106A1/en
not_active
Expired

1983-07-22
PT
PT77087A
patent/PT77087B/en
unknown

1985

1985-01-16
ES
ES539615A
patent/ES8607915A1/en
not_active
Expired

1985-01-16
ES
ES539614A
patent/ES8607936A1/en
not_active
Expired

1985-06-14
ES
ES544189A
patent/ES8700231A1/en
not_active
Expired

1989

1989-09-07
JP
JP1230574A
patent/JPH02131462A/en
active
Pending

1990

1990-11-08
HK
HK926/90A
patent/HK92690A/en
not_active
IP Right Cessation

1991

1991-12-20
CS
CS913999A
patent/CS399991A3/en
unknown

1992

1992-06-26
MX
MX9203451A
patent/MX9203451A/en
unknown

1995

1995-11-27
NL
NL950029C
patent/NL950029I2/en
unknown

1996

1996-12-10
NO
NO1996014C
patent/NO1996014I1/en
unknown

Also Published As

Publication number
Publication date

ES8607936A1
(en)

1986-06-01

NO832599L
(en)

1984-01-24

GR79232B
(en)

1984-10-22

NO164974C
(en)

1990-12-05

ES8607915A1
(en)

1986-06-01

LU88769I2
(en)

1996-11-05

JPH02131462A
(en)

1990-05-21

PT77087B
(en)

1986-01-27

ZA835182B
(en)

1984-05-30

JPH0432061B2
(en)

1992-05-28

ES524392A0
(en)

1985-11-01

FI832644A
(en)

1984-01-24

US4636505A
(en)

1987-01-13

HU191296B
(en)

1987-02-27

ES8601106A1
(en)

1985-11-01

JPS5933250A
(en)

1984-02-23

NL950029I2
(en)

1997-03-03

NL950029I1
(en)

1996-02-01

FI83770B
(en)

1991-05-15

ES8700231A1
(en)

1986-09-16

IE831732L
(en)

1984-01-23

NZ204995A
(en)

1985-08-30

EP0100172A1
(en)

1984-02-08

PT77087A
(en)

1983-08-01

NO1996014I1
(en)

1996-12-10

ES539614A0
(en)

1986-06-01

ES539615A0
(en)

1986-06-01

DK322783D0
(en)

1983-07-13

DE3372965D1
(en)

1987-09-17

EP0100172B1
(en)

1987-08-12

MX9203451A
(en)

1992-08-01

IL69217A0
(en)

1983-11-30

CS399991A3
(en)

1992-06-17

IL69217A
(en)

1987-03-31

HK92690A
(en)

1990-11-16

FI83770C
(en)

1991-08-26

IE55941B1
(en)

1991-02-27

FI832644A0
(en)

1983-07-20

ATE28864T1
(en)

1987-08-15

NO164974B
(en)

1990-08-27

AU556328B2
(en)

1986-10-30

CA1249823A
(en)

1989-02-07

ES544189A0
(en)

1986-09-16

Similar Documents

Publication
Publication Date
Title

AU556328B2
(en)

1986-10-30

Amides

JPH0144170B2
(en)

1989-09-26

ES8402696A1
(en)

1984-03-16

Hetero-cyclic substituted (halogen) alkyl and alkoxy sulfonyl urea, process for their preparation and their use in agriculture.

AU563453B2
(en)

1987-07-09

Substituted 4h-3,1-benzoxazin-2-ones

ES8705853A1
(en)

1987-05-16

Benzoylurea derivatives.

DK11184A
(en)

1985-07-12

amide derivatives

ES8406156A1
(en)

1984-08-01

N-pteridinyl ureas, process for their preparation and their use.

IT1122376B
(en)

1986-04-23

DIURETIC PRODUCTS

ES466026A1
(en)

1978-10-01

Process for the production of novel hydroxyalkyl dithiocarbamates

OA07324A
(en)

1984-08-31

Oximino-acetonilides, their production process and their use as pesticides.

ES8106288A1
(en)

1981-08-01

N-(2-isobutyronitrile sulfenyl)-N-methyl-oxime carbamates, process for their preparation and their use as pesticides.

IL76155A0
(en)

1985-12-31

Benzoylurea derivatives,their preparation and pesticidal compositions containing them

IL76156A0
(en)

1985-12-31

Benzoylurea derivatives,their preparation and pesticidal compositions containing them

GB2016454A
(en)

1979-09-26

N-(2-aminocycloheptyl) acylanilides

Legal Events

Date
Code
Title
Description

2001-02-01
PC
Assignment registered

Owner name:
ASTRAZENECA AB

Free format text:
FORMER OWNER WAS: ZENECA LIMITED

Download PDF in English